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Background: Currently there is no guideline for the treatment of patients with Crohn’s disease and high perianal
fistulas. Most patients receive anti-TNF medication, but no long-term results of this expensive medication have been
described, nor has its efficiency been compared to surgical strategies. With this study, we hope to provide treatment
consensus for daily clinical practice with reduction in costs.
Methods/Design: This is a multicentre, randomized controlled trial. Patients with Crohn’s disease who are over 18
years of age, with newly diagnosed or recurrent active high perianal fistulas, with one internal opening and no
anti-TNF usage in the past three months will be considered. Patients with proctitis, recto-vaginal fistulas or anal
stenosis will be excluded. Prior to randomisation, an MRI and ileocolonoscopy are required. All treatment will start
with seton placement and a course of antibiotics. Patients will then be randomised to: (1) chronic seton drainage
(with oral 6-mercaptopurine (6MP)) for one year, (2) anti-TNF medication (with 6MP) for one year (seton removal
after six weeks) or (3) advancement plasty after eight weeks of seton drainage (under four months anti-TNF and
6MP for one year). The primary outcome parameter is the number of patients needing fistula-related re-intervention(s).
Secondary outcomes are the number of patients with closed fistulas (based on an evaluated MRI score) after 18
months, disease activity, quality of life and costs.
Discussion: The PISA trial is a multicentre, randomised controlled trial of patients with Crohn’s disease and high
perianal fistulas. With the comparison of three generally accepted treatment strategies, we will be able to comment on
the efficiency of the various treatment strategies, with respect to several long-term outcome parameters.
Trial registration: Nederlands Trial Register identifier: NTR4137 (registered on 23 August 2013).
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Crohn’s disease (CD) is a chronic disease that typically
affects young adults, with a lifetime risk of fistula devel-
opment ranging from 14 to 38 % in population-based
estimates [1]. Perianal fistulising CD is associated with
local pain, discharge and considerable morbidity rates
(including sphincter and perineal tissue destruction),
resulting in a negative impact on quality of life [2]. The
impact on health care resources is enormous due to
multiple surgical interventions and costly medication.
Yearly, 200 million Euros are spent on anti-tumour ne-
crosis factor inhibitors (anti-TNF) for inflammatory
bowel diseases (IBD) in The Netherlands alone, of
which 90 % is for CD and 36 million Euros of that is
for fistulising CD.
There are several treatment options for complex high
fistulas (defined as the involvement of the upper two-
thirds of the external sphincter) with one internal opening.
Complete closure and fibrosis of the fistula tract can be
achieved either via a surgical approach or with medical
treatment. Until several decades ago, the most frequently
used treatment approach has been surgical seton place-
ment for chronic drainage of the fistula. A seton maintains
patency of the tract and eliminates the accumulation of
pus, which prevents the recurrent formation of tracts and
abscesses, with subsequent low re-intervention rates (10
to 20 %) [3]. However, the seton has been reported to
negatively influence quality of life and is associated with a
decreased Perianal Disease Activity Index (PDAI) score
[4]. Another disadvantage of this technique is that the fis-
tula will not close with the seton in situ. It remains un-
clear when the seton can be removed, and whether the
tract heals after removal.
Another surgical treatment option is closure of the in-
ternal fistula opening by creating an advancement plasty.
This is usually done after primary seton drainage for sev-
eral weeks. In a recent systematic review, the success rate
of endorectal advancement plasty for CD fistulas was 64
%. These results seem quite promising, although almost
10% described faecal incontinence and re-interventions
were needed in almost 50 % of patients [5].
With the introduction of anti-TNF agents (infliximab
and adalimumab), the treatment for CD fistulas has
changed from almost exclusively surgical to placing a
much larger emphasis on medical therapy [6]. Since the
results of two large trials assessing the benefit of anti-TNF
medication, almost all patients receive this medication
[7, 8]. The ACCENT I study demonstrated a significant
increase in fistula closure with infliximab when compared
to placebo treatment (55 % versus 13 % , P = 0.001) [7]. In
addition, the number of hospitalisations and surgical in-
terventions was significantly reduced by almost 50 % (65
versus 126 procedures per 100 patients, P <0.01). An
open-label adalimumab trial (CHOICE trial) demonstrateda 39 % fistula healing rate in 88 patients with CD fistulas
[8]. Unfortunately, both trials included patients with all
fistulising disease (not only perianal), and only a few
cohort studies on infliximab present specific data for
perianal fistulas, with successful closure rates ranging
from 20 to 50 % [9–13]. However, the results are diffi-
cult to translate into daily clinical practice since these
studies only demonstrated short-term results (follow-up
period of 10 to 26 weeks).
There are only a few studies presenting follow-up results
over six months. Lichtenstein et al. showed that the me-
dian length of time during which the fistulas remained
closed was three months, with over 50 % re-opening after
cessation of medication [14]. The long-term results of the
ACCENT II trial showed complete fistula closure in 34 %
of patients responding to infliximab therapy after 46
weeks versus 19 % in the placebo group [15]. So far, there
are no guidelines for stopping this therapy that is associ-
ated with high costs and several side effects. In most stud-
ies, more than 60 % of patients experience adverse events
(such as headache, infection, and fatigue) [7, 8], and the
medication affects the immune system, with potentially
serious side effects (such as infections). At present, there
is no consensus on treatment for these fistulas, and vari-
ous approaches are associated with considerable discrep-
ancies in efficiencies and costs.
Methods/Design
Study objectives
With this study, we will prospectively assess efficiency as
well as efficacy of three generally accepted treatment strat-
egies for high perianal fistulas in patients with CD. With the
results, we hope to provide treatment consensus for daily
practice with a subsequent reduction in treatment costs.
Study design
The PISA trial is a multicentre, randomized controlled trial
(RCT). Patients will be randomised to chronic seton drain-
age, anti-TNF treatment, or advancement plasty (Fig. 1).
Primary and secondary outcomes
The primary objective of this study is to analyse the
number of patients that need a re-intervention due to
fistula-related complications (abscesses, recurrent or new
tract formation) within one year. The secondary outcomes
parameters will be the number of patients with closed fis-
tulas (based on magnetic resonance imaging (MRI) find-
ings) after 18 months, disease activity (based on the
Perianal Disease Activity Index (PDAI score)), number of
necessary antibiotic courses during fistula treatment and
quality of life (measured using the Euroqol 5-dimension
questionnaire with 3 levels (EQ-5D-3 L) and the Inflamma-
tory Bowel Disease Questionnaire (IBDQ)). Furthermore,
the number of sick leave or in-hospital days, and the related
Fig. 1 Flowchart of study inclusion and follow-up procedure with outcome parameters. anti-TNF: anti-tumour necrosis factor inhibitors;
MRI: magnetic resonance imaging; AB: antibiotic; 6MP: 6-mercaptopurine; N: number; QOL: quality of life; EQ-5D: Euroqol 5D; IBDQ: Inflammatory Bowel
Disease Questionnaire; PDAI: Perianal Disease Activity Index; CEA: cost-effectiveness analysis; BIA: budget impact analysis
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(CEA) and a budget impact analysis (BIA).
Study population
All eligible patients with CD and a newly diagnosed peri-
anal fistula or an existing fistula that has recently be-
come productive or symptomatic will be considered for
inclusion. Patients can be included if they meet all of the
following inclusion criteria:
1. are ≥18-years-old;
2. have been diagnosed with CD;
3. have at least one high tract (intersphincteric,
transsphincteric or suprasphincteric) perianal fistula
located in the upper two thirds of the external
sphincter;4. have a fistula with one internal opening, based on
MRI imaging (the number of external fistulas does
not have to be taken into account);
5. have new fistulas and/or recurrent active fistulas
(defined as any producing fistula).
Patients will be excluded if they meet any of the fol-
lowing criteria:
1. Proctitis (defined as any active mucosal
inflammation or ulcer >5 mm in the rectum);
2. Anorectal stenosis (defined as the impossibility of
introducing a proctoscope);
3. Submucosal fistulas and low intersphincteric fistulas
(lower third of external sphincter);
4. Rectovaginal fistula;
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6. Seton in situ for more than three months;
7. Use of anti-TNF medication during the last three
months;
8. Previous anti-TNF medication without any effect on
perianal fistulas;
9. Previously demonstrated allergy for anti-TNF medi-
cation. If this allergy only concerns the chimeric
monoclonal mouse-antibody infliximab, the patient
could be randomised for adalimumab;
10.Patients with a stoma;
11.Immunocompromised patients, including those with
haematological malignancies, HIV or AIDS, bone
marrow transplantation, splenectomy, genetic
disorders such as severe combined
immunodeficiency, chemotherapy, dialysis, solid
organ transplant and long-term immunosuppressant
use such as corticosteroids in patients with rheumatoid
arthritis);
12.Life expectancy of less than two years;
13.The inability of reading and understanding, and
filling in the questionnaires;
14.Dementia or altered mental status that would
prohibit the understanding and giving of informed
consent.
Participating centres
Up until now, 13 centres in The Netherlands, including six
academic centres, will enrol patients. In addition, a centre
in Italy, Ireland and two centres in England will participate.
Ethics
The study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and ‘good clinical
practice’ guidelines. The protocol has been approved by
the Medical Ethical Committee of the Academic Medical
Center in Amsterdam (METC 2013_201). Consent was
also obtained from the participating centres (Additional
file 1). Patients with CD and presenting with a perianal
fistula will be counselled, and written informed consent
will be obtained from all patients if the inclusion and ex-
clusion criteria are met.
Study outline
Eligible patients will be recruited at the IBD outpatient
department of each participating medical centre. At
inclusion, an MRI will be performed to assess the course
of the fistula tracts, the number of internal openings and
to exclude concurrent perianal abscesses. Prior to ran-
domisation, an ileocolonoscopy is necessary to exclude
proctitis. In case it is not possible to perform an ileocolo-
noscopy, a sigmoidoscopy and Magnetic Resonance
Enteroclysis (MRE) must be performed prior to random-
isation. If during this investigation luminal disease activityis observed, patients will receive standard treatment, start-
ing with an eight-week prednisolone course, dosing at the
discretion of the treating physician, together with an im-
munomodulator of either oral 6-mercaptopurine (6MP) 1
to 1.5 mg/kg or oral azathioprine 2 to 2.5 mg/kg or sub-
cutaneous methotrexate 25 mg/week. At week 12, step-up
to anti-TNF (infliximab or adalimumab) in case of insuffi-
cient response of luminal disease activity to steroids or the
immunomodulator is allowed. These patients will not be
excluded from the trial.
Randomisation and blinding
Random block randomisation of consented study partici-
pants will be performed by an internet randomisation
module prepared by the Clinical Research Unit of the
Academic Medical Center. Randomisation will not be
stratified. Due to the comparison of surgical and medical
treatment strategies in this study, blinding to the treat-
ment allocation for patient and medical staff is not pos-
sible. The statistician will analyse the data blinded for
treatment allocation.
Chronic seton drainage
Treatment for the seton group is scheduled to last for
one year. Seton (vessel loop) placement will be performed
under general anaesthesia in a day care setting and pa-
tients will receive a two-week antibiotic course of cipro-
flaxin 500 mg twice a day; in case of non-responsiveness,
patients will switch to metronidazole 500 mg three
times a day for two weeks). Medical treatment with
6MP (Puri-nethol by Aspen Pharma Trading Limited,
Dublin, Ireland) will be added 1 to 1.5 mg/kg.
Anti-TNF
Patients randomly allocated to the second treatment
arm will also start with the insertion of a seton and a
two-week antibiotic course. Then, anti-TNF treatment
will be initiated combined with 6MP. The anti-TNF
choice (infliximab (REMICADE by Janssen Biologics
Inc., Pennsylvania, USA) and adalimumab (HUMIRA by
AbbVie Biotechnology GmbH, Wiesbaden Germany))
will be left to the discretion of the treating gastroenter-
ologist. The anti-TNF agent consists of infliximab 5 mg/
kg at the beginning of treatment, which will be repeated
at two and six weeks as a loading dose. After this, treat-
ment will be scheduled for every eight weeks. If a patient
is non-responsive to the treatment dose escalation to 5
mg/kg every six weeks is permitted. When adalimumab
is the preferable anti-TNF agent, a loading dose of 160
mg at the start of treatment is required. After two
weeks, the dosage will be reduced to 80 mg, and then
continued with 40 mg every two weeks. If a patient is
non-responsive, dose escalation is allowed to up to 40
mg a week. After six weeks, the seton will be removed.
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year.Advancement plasty
In the advancement plasty group, treatment also starts
with the insertion of a seton and a two-week antibiotic
course. Subsequently this group will start with anti-
TNF treatment combined with 6MP. The advancement
plasty will be performed in a day-care setting (directly
following seton removal) within eight to 10 weeks after
randomisation, when the anti-TNF agent has reached
therapeutic levels. The anti-TNF medication will be
continued until four months after randomisation. For
optimal results the procedure must be performed by a
specialised colorectal surgeon. When participating cen-
tres lack a qualified surgeon, the patient will be referred
to the Academic Medical Center.Statistical analysis
The outcome parameters will be analysed with appropri-
ate statistical tests by a statistician on an intention-to-
treat basis, using the statistical program IBM SPSS Sta-
tistics for Windows, Version 21.0. Armonk, NY: IBM
Corp.. A two-tailed P <0.05 is considered statistically sig-
nificant. Analyses will be presented with 95 % confidence
intervals. The primary and secondary outcome parame-
ters, the proportion of patients in need of re-
interventions and the proportion of patients with closed
fistulas respectively, will be compared with chi-squared
testing. The difference in number of re-interventions be-
tween the three groups will be compared using Kruskal
Wallis testing. Additional mixed-models repeated mea-
sures analysis of variance will be used to investigate
whether there is a different pattern of change over time
between the three study arms in the four IBDQ dimen-
sions and the EQ 5D-3 L.Sample size calculation
The principal analysis will consist of an intention-to-
treat comparison of the proportions of patients with
fistula-related interventions in the three treatment
groups. The goal is to test superiority of chronic seton
drainage over the other two groups. Based on the avail-
able literature with re-interventions in 50 % of patients
in the anti-TNF group and advancement plasty group,
an absolute reduction to between 30 and 20 % of pa-
tients needing a re-intervention in the chronic seton
group is considered clinically relevant and feasible. The
sample size needed to detect this difference with two-
sided chi-squared testing equals 42 patients per group,
or 126 patients overall (alpha 0.05, power 80 % and 5 %
dropout rate).Data collection and monitoring
Patients will be seen at the outpatient clinic at regular
intervals after randomisation by the surgeon or the
gastroenterologist, depending on the assigned treatment
strategy. Thereafter, all patients will be seen at six, 12 and
18 months after inclusion. Other visits will be scheduled
on indication. During these contacts the PDAI score will
be assessed. Patients will fill in health-related quality of life
questionnaires (EQ-5D-3 L, IBDQ and the Modified
Health and Labour Questionnaire) at inclusion and every
three months after. The questionnaires will be completed
by patients electronically using LimeSurvey 1.90 via
https://www.limesurvey.org/en/, a personal access code
sent by email. Patients not willing or unable to complete
the online questionnaires will receive identical paper ques-
tionnaires at their home address, accompanied by a free
return envelope. An electronic case report form will in-
clude general patient data. Patients will be followed by a
trial nurse to assess complications, re-admissions, dur-
ation of hospital stay and the number of sick leave days.
After 18 months patients will undergo an MRI to assess
fistula closure, or at the suspicion of an abscess or new fis-
tula tract. An evaluated MRI-based score will be used to
classify disease severity for perianal fistulising CD [16].
Patient safety
All three treatment strategies are generally accepted,
therefore there is no additional risk. However, an interim
review will be performed after one year of follow-up for
one third of included patients (n = 42), and after one-year
of follow-up for two thirds of included patients (n = 84).
The Data and Safety Monitoring Board (DSMB) will be
supplied with the number of (serious) adverse events and
other outcome parameters in all three groups at this time.
If there is a skewed distribution of the number of (serious)
adverse events between the groups, an efficacy analysis
can be performed at the discretion of the DSMB. Follow-
ing this interim analysis, the DSMB will advise the study
Steering Committee upon continuation of the trial.
Cost-effectiveness and cost-utility
An economic evaluation will be performed from a societal
perspective as a cost-effectiveness and cost-utility analysis
with a time horizon of 18 months. The primary economic
outcomes are the costs per patient with re-interventions
and the costs per quality adjusted life year (QALY), re-
spectively. The CEA closely relates to the primary clinical
outcome measure; the cost-utility analysis is performed to
support health policymakers in allocating health care re-
sources across patient groups, health care settings and in-
terventions. Incremental cost-effectiveness ratios of each
alternative treatment (anti-TNF or advancement plasty)
against chronic seton drainage as the reference strategy
will be calculated as the extra costs per additional patient
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itional QALY. To account for sampling variability, differ-
ences between groups will be assessed by calculating the
95 % confidence intervals, after correction for bias, and
using accelerated non-parametric bootstrapping. Results
will be displayed graphically with cost-effectiveness planes
and cost-effectiveness acceptability curves for willingness-
to-pay values up to €100,000. Sensitivity analyses will be
performed for the unit costs of (chronic) seton drainage,
advancement plasty and anti-TNF medication. Sensitivity
analysis will also be performed for different (Dutch and
UK general population based) health utility scoring algo-
rithms used to derive QALYs. Considering the time hori-
zon of 18 months, we will discount the effects and costs
during the second year of follow-up.
Data on health care resource use (index interventions, re-
interventions, hospitalisations and out-of-hospital care),
health-related out-of-pocket expenses by patients and prod-
uctivity losses resulting from sick leave will either be re-
trieved from hospital information systems, or gathered with
clinical report forms and tailored patient questionnaires.
Unit costing of resources used will be in accordance with
current national guidelines (CvZ/EUR-iMTA: College voor
Zorgverzekeringen/Erasmus Universitu Rotterdam-institute
for Medical Technology Assessment). In case of productivity
losses resulting from sick leave or lower efficiency while at
work, the friction cost approach to costing will be applied.
All costs will be expressed in Euros for the base year 2013.
Costs borne in other calendar years will be price indexed.
Perianal fistulas in CD may heavily affect a person’s qual-
ity of life. Affected patients experience pain and feel re-
stricted in daily activities as well as in sexual activities. At
present, the PDAI is the gold standard for evaluating the se-
verity of perianal disease. It includes five items: discharge,
pain, restriction of sexual activity, type of perianal disease
and degree of induration. Each category is graded on a five-
point Likert scale ranging from no symptoms to severe
symptoms. The PDAI will be disseminated at baseline and
half-yearly thereafter. In addition, the EQ-5D-3 L will be
used to gather health status profiles over time (baseline and
at quarterly intervals). These profiles will be evaluated by
applying existing time trade-off based health utility scoring
algorithms from previous research among general adult
populations in The Netherlands and the UK [17, 18].
QALYs will then be calculated by taking the product sum
of the resulting health utilities and the length of the periods
in-between successive measurements. All patient outcome
data will be analysed as repeated measurements by linear
mixed modelling.
Budget impact
The short- and mid-term budget impacts of the three treat-
ment strategies will be assessed from governmental and in-
surer perspectives in accordance with a recent InternationalSociety for Pharmacoeconomics and Outcomes Research
(ISPOR) guideline [19]. Budget impact analyses may guide
reimbursement decisions and may influence price and vol-
ume negotiations between insurer and health care provider.
In this study, the budget impact analyses will be incidence-
based, concerning patients with CD that are newly diag-
nosed with a perianal fistula. At the same time, the analyses
will be patient-based, covering all health care costs ob-
served during the 18 months of follow-up. At this time, the
treatment strategies will presumably end up with compar-
able proportions of patients with complete fistula closure.
The governmental perspective is chosen to help set prior-
ities in health care optimization while simultaneously con-
sidering the wider implications of the seton drainage, anti-
TNF medication and advancement plasty beyond the health
care sector (societal impact). The governmental perspective
further includes an impact assessment on budgets for insti-
tutions for specialist medical care, self-employed medical
specialists and (expensive) drugs (Rijksbegroting 2012, pre-
mie gefinancierde zorg (http://www.rijksbegroting.nl/2012/
voorbereiding/begroting,kst160371_3.html). The insurer
perspective is chosen to assess the net financial conse-
quences of replacing anti-TNF drug therapy with the seton
drainage or advancement plasty strategies. Hence, against
the base case scenario of predominantly anti-TNF medica-
tion supply, we will assess the impact of an instant, gradual
or partial shift to seton drainage or to advancement plasty.
As with the CEA, sensitivity analyses will be performed for
the unit costs of (chronic) seton drainage, advancement
plasty and anti-TNF medication. The time horizon for all
budget impact assessments will be four years and will be re-
ported for each successive calendar year.
Discussion
High perianal fistulas in patients with CD have an enormous
impact on patients’ quality of life, as well as on health care
systems [2]. Our goal is to provide evidence for optimal
treatment resulting in (inter)national consensus of all disci-
plines involved in the treatment of these patients. All three
treatment approaches are currently included in the basic
health insurance packages and the Dutch Exceptional Med-
ical Expenses Act 1968 (AWBZ). In the three study groups,
an optimal combination of available treatment regimens will
be provided. Every patient starts with seton drainage to cre-
ate a patent tract and to reduce inflammation, preventing
the accumulation of pus. This will be accompanied by the
prescription of a two-week antibiotics course, since the
ADAFI study demonstrated that anti-TNF therapy is more
effective in combination with a course of ciprofloxacin [20].
The anti-TNF medication will be combined with 6MP to
optimise the result of the anti-TNF medication, since
Colombel et al. established that patients receiving combin-
ation therapy were more likely to have corticosteroid-free
clinical remission [21]. In the ECCO guideline of 2010,
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combination with appropriate surgical therapy for complex
perianal CD, in spite of a lack of clinical trials. Therefore,
the patients in the surgical arms will also be treated with
azathioprine or 6MP [22]. Since it has been described that
the success rate of advancement plasty is slightly higher
when combined with anti-TNF therapy (50 % versus 65 %)
[5], this group will receive medication for four months.
Once the fistula is closed, anti-TNF medication is not likely
to have any additional value and will be discontinued.
Based on the available literature, superiority for chronic
seton drainage with respect to the number of re-
interventions is expected. Both anti-TNF medication and
advancement plasty have been described to have up to a 50
% re-intervention rate due to recurrent fistulas or abscess
formation, whereas this is hardly seen in chronic seton
drainage due to preservation of a patent tract. We hypothe-
sise that after 18 months, no differences will be found in
the number of patients with draining fistulas for all three
groups described previously. Studies presenting the long-
term results for seton drainage describe up to 40 % closure
of fistulas after seton removal [23–27]. This is in line with
the sparse literature on long-term results for anti-TNF
medication or advancement plasty results. For advancement
plasty, the initial results show up to 65 % success rates, but
recurrences occur in a substantial subset of patients, and
this technique has been associated with decreased functional
outcome with faecal incontinence occurring in 10 % of cases
[5]. For anti-TNF medication, a 40 to 60 % initial closure
rate has been described, but one study with long-term re-
sults demonstrated that 50 % of the responding patients had
recurrent fistulas after cessation of therapy [14]. When com-
bining these results, it can be expected that surgical drainage
will be highly cost-effective. Treatment strategies will be
stopped after one year, while patients will be followed up on
for another six months, in order to comment on long-term
results. With the comparison of these three groups, we will
be able to comment on the efficiency of the various treat-
ment strategies with respect to several long-term outcome
parameters.Trial status
In total, we currently included 16 patients in the PISA
trial at the time of submission of the protocol to Trials
(17 June 2015). The first patient was included in the
Academic Medical Center on 1 November 2013. In 2014
and 2015, the other participating centres were added to
the trial. In the supplementary file, dates of consent in
the participating centres are specified.
Additional file
Additional file 1: Dates of consent of participating centres.Abbreviations
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